Loading…
Protecting Free Trade in Pharmaceuticals Act of 2005
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,105 other S bills in the 109th — cohort avg 35d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2006 · year_end · Trade (domestic/foreign)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Legislation regarding duty suspension for Ezetimibe: H.R.2077, To suspend temporarily the duty on Garenoxacin mesylate; H.R.2079, To extend the temporary duty suspension on Ezetimibe; S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005. H.R.2077, To suspend temporarily the duty on Garenoxacin mesylate; H.R.2079, To extend the temporary duty suspension on Ezetimibe; S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005.
Client expense: $860,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2006 · year_end · Pharmacy
S.109, Pharmaceutical Market Access Act of 2005, S.184, Safe IMPORT Act of 2005, Safe Importation of Medical Products and Other Rx Therapies Act of 2005, S.334, Pharmaceutical Market Access and Drug Safety Act of 2005, General discussion regarding drug reimportation, pharmaceutical distribution issues, recent issues with importation and adulterated drugs, ordering and dispensing technology related to hospital pharmacy and out-patient pharmacy activities, drug pricing, prescription drug discount cards, internet drug sales, S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005, H.R.2345, Counterfeit Drug Enforcement Act of 2005, H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005, FY2005 Appropriations Act for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, S.2668, Reducing Fraudulent and Imitation Drugs Act of 2006, S.2582, Preserve Access to Affordable Generics Act, H.R.5156, Counterfeit Drug Prevention Act of 2006, S.2315, Methamphetamine Awareness and Prevention Act of 2006, H.R.4763, Methamphetamine Education Act, H.R.4829, Reducing Fraudulent and Imitation Drugs Act of 2006 H.R.314, Combat Meth Act of 2005, H.R.328, Pharmaceutical Market Access Act of 2005, S.103, Combat Meth Act of 2005,
Client expense: $320,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2006 · year_end · Utilities
S. 1551 - Climate Stewardship & Innovation Act of 2005 Implementation of H.R. 6, the Energy Policy Act, provisions dealing with nuclear energy S. 680/H.R. 1834 - the EFFECTER Act, provisions dealing with energy efficiency programs & tax incentives H.R. 3893 - Gasoline for America's Security Act of 2005, provisions dealing with refineries
Client expense: Not reported · Firm income: $80,000
Government targets: Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, SENATE
2006 · year_end · Trade (domestic/foreign)
Legislation regarding duty suspension for Ezetimibe: H.R.2077, To suspend temporarily the duty on Garenoxacin mesylate; H.R.2079, To extend the temporary duty suspension on Ezetimibe; S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005. H.R.2077, To suspend temporarily the duty on Garenoxacin mesylate; H.R.2079, To extend the temporary duty suspension on Ezetimibe; S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005.
Client expense: $820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2006 · year_end · Pharmacy
S.109, Pharmaceutical Market Access Act of 2005, S.184, Safe IMPORT Act of 2005, Safe Importation of Medical Products and Other Rx Therapies Act of 2005, S.334, Pharmaceutical Market Access and Drug Safety Act of 2005, General discussion regarding drug reimportation, pharmaceutical distribution issues, recent issues with importation and adulterated drugs, ordering and dispensing technology related to hospital pharmacy and out-patient pharmacy activities, drug pricing, prescription drug discount cards, internet drug sales, S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005, H.R.2345, Counterfeit Drug Enforcement Act of 2005, H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005, FY2005 Appropriations Act for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, S.2668, Reducing Fraudulent and Imitation Drugs Act of 2006, S.2582, Preserve Access to Affordable Generics Act, H.R.5156, Counterfeit Drug Prevention Act of 2006, S.2315, Methamphetamine Awareness and Prevention Act of 2006, H.R.4763, Methamphetamine Education Act, H.R.4829, Reducing Fraudulent and Imitation Drugs Act of 2006 H.R.314, Combat Meth Act of 2005, H.R.328, Pharmaceutical Market Access Act of 2005, S.103, Combat Meth Act of 2005,
Client expense: Not reported · Firm income: $40,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2006 · year_end · Pharmacy
1. S. 334, HR 700, S. 1551, S. 109, HR 2744-Specifically, provisions relating to the importation of prescription drugs. 2. S. 930-A bill to amend the Food and Drug Administration Safety Act, with respect to drug safety.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2005 · mid_year · Pharmacy
1. S. 334, HR 700, S. 1551, S. 109, HR 2744 - Specifically, provisions relating to the importation of prescription drugs. 2. S. 930 - A bill to amend the Food and Drug Administration Safety Act with respect to Drug Safety
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2005 · mid_year · Pharmacy
1. S. 334, HR 700, S. 1551, S. 109, HR 2744 - Specifically, provisions relating to the importation of prescription drugs. 2. S. 930 - A bill to amend the Food and Drug Administration Safety Act with respect to Drug Safety
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE